Oligonucleotide Therapies for Facioscapulohumeral Muscular Dystrophy: Current Preclinical Landscape
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25169065 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Samuel L Beck und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Faculty of Science, University of Alberta, Edmonton, AB T6G 2R3, Canada. Hauptthemen laut MEDLINE: Muscular Dystrophy, Facioscapulohumeral, Homeodomain Proteins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Muscular Dystrophy Canada, the Canadian Institutes of Health Research (CIHR), the Women and Children’s Health Research Institute (WCHRI).
Abstract (Originalsprache)
Facioscapulohumeral muscular dystrophy (FSHD) is an inherited myopathy, characterized by progressive and asymmetric muscle atrophy, primarily affecting muscles of the face, shoulder girdle, and upper arms before affecting muscles of the lower extremities with age and greater disease severity. FSHD is a disabling condition, and patients may also present with various extramuscular symptoms. FSHD is caused by the aberrant expression of double homeobox 4 (DUX4) in skeletal muscle, arising from compromised epigenetic repression of the D4Z4 array. DUX4 encodes the DUX4 protein, a transcription factor that activates myotoxic gene programs to produce the FSHD pathology. Therefore, sequence-specific oligonucleotides aimed at reducing DUX4 levels in patients is a compelling therapeutic approach, and one that has received considerable research interest over the last decade. This review aims to describe the current preclinical landscape of oligonucleotide therapies for FSHD. This includes outlining the mechanism of action of each therapy and summarizing the preclinical results obtained regarding their efficacy in cellular and/or murine disease models. The scope of this review is limited to oligonucleotide-based therapies that inhibit the DUX4 gene, mRNA, or protein in a way that does not involve gene editing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, Faculty of Science, University of Alberta, Edmonton, AB T6G 2R3, Canada.
- Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Förderung
- Muscular Dystrophy Canada
- the Canadian Institutes of Health Research (CIHR)
- the Women and Children’s Health Research Institute (WCHRI)
- US Department of Defense
- Gilbert K Winter Fund
- Heart and Stroke Foundation Canada
Zitieren
APA
Beck, S. L., & Yokota, T. (2024). Oligonucleotide Therapies for Facioscapulohumeral Muscular Dystrophy: Current Preclinical Landscape. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25169065
Vancouver
Beck SL, Yokota T. Oligonucleotide Therapies for Facioscapulohumeral Muscular Dystrophy: Current Preclinical Landscape. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25169065
BibTeX
@article{Beck2024,
author = {Beck, Samuel L and Yokota, Toshifumi},
title = {Oligonucleotide Therapies for Facioscapulohumeral Muscular Dystrophy: Current Preclinical Landscape},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25169065}
}
EUVIMED